Mucosa-associated lymphoid tissue lymphoma

Current Opinion in Hematology

Volumn 9, Issue 1, 2002, Pages 50-55

  Wotherspoon, A C ^a   Dogan, A ^a   Du, M Q ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; GENE PRODUCT; PROTEIN BCL 10; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; CONJUNCTIVA TUMOR; ENDOSCOPIC ECHOGRAPHY; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; LYMPH NODE; LYMPHOID TISSUE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR REGRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; TRANSLOCATION, GENETIC;

EID: 0036134972     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200201000-00009     Document Type: Review

References (54)

1. Malignant lymphoma of mucosa associated lymphoid tissue. A distinctive type of B-cell lymphoma
2. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma
3. Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas
4. H. pylori-associated gastric lymphoma
5. Pathogenesis of gastric lymphoma: The enigma in Hong Kong
6. Evaluation of Helicobacter pylori in gastric MALT-type lymphoma: Differences between histologic and serologic diagnosis
7. Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients
8. A comparison of Helicobacter pylori and H. heilmannii gastritis. A matched control study involving 404 patients
9. Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori
10. Regression of MALT lymphoma of the rectum after anti-H. pylori therapy in a patient negative for H. pylori
11. Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori
12. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed
13. Multiple organ mucosa-associated lymphoid tissue lymphomas often involve the intestine
14. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas
15. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type
16. The apoptosis inhibitor gene APl2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6-associated with mucosa-associated lymphoid tissue lymphomas
17. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue
18. BCL10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types
19. Inactivating mutations and overexpressionn of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32)
20. Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma
21. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue
22. Trisomy 3 in marginal zone B-cell lymphoma: A study based on cytogenetic analysis and fluorescence in situ hybridization
23. Identification of paracaspases and metacaspases: Two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma
24. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas
25. The product of the t(11;18), an API2-MLT fusion, is an almost exclusive finding in marginal zone cell lymphoma of extranodal MALT-type
26. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation
27. BCL10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types
28. BCL10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure
29. BCL10 gene mutation in lymphoma
30. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma
31. t(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10
32. Bimp1, a MAGUK family member linking protein kinase C activation to BCL10-mediated NF-kappaB induction
33. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity
34. Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development
35. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma
36. Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas
37. The bcl-2 gene in primary B cell lymphoma of mucosa-associated lymphoid tissue (MALT)
38. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas
39. C-myc gene abnormalities in mucosa associated lymphoid tissue (MALT) lymphomas
40. Regression of primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
41. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection
42. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma
43. Eradication of Helicobacter pylori and stability of remissions in low-grade gastric B-cell lymphomas of the mucosa-associated lymphoid tissue: Results of an ongoing multicentre trial
44. Histological and immunological parameters to predict treatment outcome of Helicobacter pylori eradication in low-grade gastric MALT lymphoma
45. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori
46. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy
47. API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma
48. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging
49. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment
50. Predictive value of endoscopic ultrasonography for regression of low grade and high grade MALT lymphomas after eradication of Helicobacter pylori
51. Treatment of low-grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up
52. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma
53. Local chemotherapy with interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma